Teladoc Health (NYSE:TDOC) Insider Adam Vandervoort Sells 7,906 Shares

Teladoc Health, Inc. (NYSE:TDOC) insider Adam Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. The trade was a 6.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Price Performance

Shares of TDOC opened at $7.08 on Thursday. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -7.30 and a beta of 2.14. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.77. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. The company has a 50 day moving average of $6.13 and a two-hundred day moving average of $6.21.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The firm had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health’s revenue was down 2.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, analysts predict that Teladoc Health, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Teladoc Health

Large investors have recently added to or reduced their stakes in the company. Essential Partners LLC purchased a new stake in shares of Teladoc Health in the first quarter worth about $113,000. Janus Henderson Group PLC boosted its stake in shares of Teladoc Health by 7.7% in the first quarter. Janus Henderson Group PLC now owns 262,215 shares of the health services provider’s stock worth $1,429,000 after buying an additional 18,679 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Teladoc Health by 694.5% in the first quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after buying an additional 4,945 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Teladoc Health by 61.2% in the first quarter. California State Teachers Retirement System now owns 274,441 shares of the health services provider’s stock worth $1,496,000 after buying an additional 104,160 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in shares of Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after buying an additional 1,471,631 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on TDOC shares. JPMorgan Chase & Co. reduced their target price on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, March 13th. Deutsche Bank Aktiengesellschaft raised Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, March 10th. Stifel Nicolaus reduced their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Wells Fargo & Company reduced their target price on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 26th. Finally, Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.43.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.